Please assess the completion status of the following clinical trial:

Trial Title: Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \>/= 15 years.~2. Previously untreated ALL, Burkitt's lymphoma, or lymphoblastic leukemia receiving induction chemotherapy with hyper-CVAD or variants of the hyper-CVAD regimen.~3. Random serum glucose \>/= 180 mg/dL detected during the first 2 cycles of chemotherapy and confirmed with a second measurement.~Exclusion Criteria:~1. History of Type I diabetes mellitus.~2. Pregnancy or breast feeding.~3. Allergy to insulin or insulin products.~4. On-going treatment of steroid-induced hyperglycemia by an endocrinologist and/or general internist.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Conventional Care (Type: NO_INTERVENTION): Control Group: Conventional care using blood sugar management with regular human insulin.
- Intensive Insulin (Type: OTHER): Intervention Group: Intense blood sugar management with Insulin Aspart + Insulin Glargine

Based on this trial design, predict the completion outcome and termination type (if applicable).